Opinion of the Transparency Council – risedronatum natricum
At its meeting on 9 December 2024, the Transparency Council adopted position No. 197/2024 on the inclusion in reimbursement of medicines containing the active substance risedronatum natricum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics, i.e. post-steroidal osteoporosis – prophylaxis